dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Mirallas Viñas, Oriol |
dc.contributor.author | Filippi Arriaga, Maria Francesca Eugenia |
dc.contributor.author | Hernández Hernández, Irene |
dc.contributor.author | Aubanell, Anton |
dc.contributor.author | Chaachou, Anas |
dc.contributor.author | Garcia-Alvarez, Alejandro |
dc.contributor.author | Hernando Cubero, Jorge |
dc.contributor.author | Martinez Saez, Elena Antima |
dc.contributor.author | Biagetti Biagetti, Betina |
dc.contributor.author | Capdevila Castillon, Jaume |
dc.date.accessioned | 2022-06-02T08:33:20Z |
dc.date.available | 2022-06-02T08:33:20Z |
dc.date.issued | 2021-11-11 |
dc.identifier.citation | Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, Garcia-Alvarez A, et al. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report. Front Endocrinol. 2021 Nov 11;12:731631. |
dc.identifier.issn | 1664-2392 |
dc.identifier.uri | https://hdl.handle.net/11351/7615 |
dc.description | Tumors hipofisaris agressius; Capecitabina; Temozolomida |
dc.language.iso | eng |
dc.publisher | Frontiers Media |
dc.relation.ispartofseries | Frontiers in Endocrinology;12 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Adenoma - Tractament |
dc.subject | Hipòfisi - Tumors - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Nelson Syndrome |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Adenoma |
dc.title | Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3389/fendo.2021.731631 |
dc.subject.decs | síndrome de Nelson |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | adenoma |
dc.relation.publishversion | https://doi.org/10.3389/fendo.2021.731631 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Mirallas O, Garcia-Alvarez A, Hernando J, Capdevila J] Servei d’Oncologia Mèdica, Unitat de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Filippi-Arriaga F] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernandez Hernandez I, Biagetti B] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chaachou A, Martínez-Saez E] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 34858324 |
dc.identifier.wos | 000727887300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |